NCT03069378View on ClinicalTrials.gov

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

July 22, 2025

Study Completion Date

March 31, 2026

Conditions
SarcomaEpithelioid SarcomaCutaneous Angiosarcoma
Interventions
DRUG

Talimogene Laherparepvec (T-VEC)

Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .

DRUG

Pembrolizumab

Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

77030

MD Anderson Cancer Center (Data Analysis Only), Houston

94025

Enable Medicine (Specimen Analysis Only), Menlo Park

94305-5408

Stanford University Medical Center, Stanford

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER